Abbott Laboratories 9MCY26 Posts 25% Profit Increase, Hitting Near Rs7 Billion

Abbott Laboratories’ fiscal year 2026 segment (9MCY26) reported a robust 25% rise in profit, reaching approximately Rs7 billion. The growth was driven by expanded product offerings, enhanced operational efficiencies, and favorable market dynamics. Industry observers regard the strong earnings as a testament to the company’s solid financial performance and promising outlook.

Source link